For Immediate Release
Continuous Glucose Monitoring for Remote Diabetes Management during the COVID-19 Pandemic
Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com
New Rochelle, NY, September 21, 2021—New case studies show the benefits of remote management based on continuous glucose monitoring (CGM) and telemedicine visits for patients with type 1 and type 2 diabetes during the COVID-19 pandemic. Use of remote monitoring technology can significantly improve glycemic control, as described in a supplement to the peer-reviewed journal Diabetes Technology & Therapeutics (DTT). The Supplement is titled “Emerging Landscape of Continuous Glucose Monitoring.” Click here to read the supplement now.
Anders Carlson, MD, from the University of Minnesota Medical School, and coauthors, present case studies of patients with type 1 and type 2 diabetes managed during the COVID-19 pandemic using CGM and telemedicine visits, including a 3-year-old patient with newly diagnosed type 1 diabetes. Current CGM systems can automatically transmit patients’ glucose data to healthcare providers for analysis.
“We found that use of telemedicine patient consults and remote monitoring of CGM and insulin data enabled us to assess glycemic control and make therapy adjustments without the potential hazards and patient burden of in-person clinic visits,” said the authors. “Moreover, our ability to review and discuss the data with our patients helped them better understand how their therapy impacted daily glucose management, which, in turn, enhanced their engagement in their daily self-management.”
Also in the supplement is an article titled “Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen.” James Gavin, III, MD, PhD, from Emory University School of Medicine, and Clifford Baily, PhD, from Aston University review findings from recent real-world studies of CGM systems. These provide greater insights into the clinical effectiveness and economic impact of this technology within various diabetes populations.
“Results from these studies suggest that wider use of CGM within the broader diabetes population could increase overall glycemic control and improve the effectiveness while reducing the enduring cost of diabetes healthcare,” state the authors.
“Results from these studies suggest that wider use of CGM within the broader diabetes population could increase overall glycemic control and improve the effectiveness while reducing the enduring cost of diabetes healthcare,” state the authors.
This supplement was supported by an educational grant from Abbott.
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, University of Colorado Denver (Aurora), the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
About ATTD
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Publisher
Mary Ann Liebert, Inc., publishers is known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s more than 100 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.